Global Oncology Academy

Predictive Models for CAR T-Cell Therapy: Personalizing R/R LBCL Care
Predictive Models for CAR T-Cell Therapy: Personalizing R/R LBCL Care
Project Oncology®
Predictive Models for CAR T-Cell Therapy: Personalizing R/R LBCL Care
- Charles Turck, PharmD, BCPS, BCCCP
- Matthew Matasar, MD
Mastering CAR-T Cell Therapy in R/R Large B-Cell Lymphoma: Adverse Event Management
Mastering CAR-T Cell Therapy in R/R Large B-Cell Lymphoma: Adverse Event Management
Project Oncology®
Mastering CAR-T Cell Therapy in R/R Large B-Cell Lymphoma: Adverse Event Management
- Charles Turck, PharmD, BCPS, BCCCP
- Sairah Ahmed, MD
- Caron A. Jacobson, MD
Preventing Adverse Events in CAR T-Cell Therapy: The Evolution of Safety Protocols
Preventing Adverse Events in CAR T-Cell Therapy: The Evolution of Safety Protocols
Project Oncology®
Preventing Adverse Events in CAR T-Cell Therapy: The Evolution of Safety Protocols
- Tara Graff, DO, MS
- Charles Turck, PharmD, BCPS, BCCCP
Preventing MGUS/SMM Progression to Multiple Myeloma with Dietary Interventions
Preventing MGUS/SMM Progression to Multiple Myeloma with Dietary Interventions
Global Oncology Academy
Preventing MGUS/SMM Progression to Multiple Myeloma with Dietary Interventions
Early-Stage Breast Cancer Care: Treatment Selection Strategies and Challenges
Early-Stage Breast Cancer Care: Treatment Selection Strategies and Challenges
Project Oncology®
Early-Stage Breast Cancer Care: Treatment Selection Strategies and Challenges
- Adrienne Waks, MD
Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations
Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations
MinuteCE®
Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations
1.50 program credits
- Peter Schmid, FRCP, MD, PhD
1.50 program credits
Management of HER2-Low MBC Following First-Line Disease Progression
Management of HER2-Low MBC Following First-Line Disease Progression
MinuteCE®
Management of HER2-Low MBC Following First-Line Disease Progression
1.50 program credits
- Peter Schmid, FRCP, MD, PhD
1.50 program credits
First-Line Advanced Gastric Cancer: Best Practices for Biomarker-Directed Treatment Approaches—A Case Study
First-Line Advanced Gastric Cancer: Best Practices for Biomarker-Directed Treatment Approaches—A Case Study
MinuteCE®
First-Line Advanced Gastric Cancer: Best Practices for Biomarker-Directed Treatment Approaches—A Case Study
1.25 program credits
- Sara Lonardi, MD
1.25 program credits

Medical News

Medical News
Open-World Video Games Found to Boost Mental Well-Being in Postgraduate Students
medicalxpress.com
01/08/2025
Read more
Medical News
Innovative Haptic Belt Shows Promise for Improving Mobility in People With Vision Loss
sciencedaily.com
01/08/2025
Read more
Medical News
New Technology Reverts Colon Cancer Cells to Normal-Like State Without Traditional Side Effects
news-medical.net
01/08/2025
Read more
Medical News
Smartphone App Reduces Opioid Use and Enhances Treatment Retention, Study Finds
news.uthscsa.edu
01/07/2025
Read more

See more news

CME/CE

Biomarker-Directed Approaches for Frontline Treatment of Advanced Gastric/GEJ Cancers: The Evidence
Biomarker-Directed Approaches for Frontline Treatment of Advanced Gastric/GEJ Cancers: The Evidence
MinuteCE®
Biomarker-Directed Approaches for Frontline Treatment of Advanced Gastric/GEJ Cancers: The Evidence
1.25 program credits
- Sara Lonardi, MD
1.25 program credits
MinuteCE®
Innovations in Oncology Learning Center: From Guidelines to Practice—Breast Cancer
1.50 credits 10 episodes
- William J. Gradishar, MD
- Erica L. Mayer, MD, MPH
- Peter Schmid, FRCP, MD, PhD
1.50 credits 10 episodes
MinuteCE®
Innovations in Oncology Learning Center From Guidelines to Practice: Gastrointestinal Cancers
1.25 credits 10 episodes
- Sara Lonardi, MD
- Aparna R. Parikh, MD
- Alan Venook, MD
1.25 credits 10 episodes
The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?
The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?
MinuteCE®
The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?
1.25 program credits
- Sara Lonardi, MD
1.25 program credits

Clinical Practice

Sacituzumab Govitecan for mTNBC: A Review of Real-World Efficacy and Safety Data
Sacituzumab Govitecan for mTNBC: A Review of Real-World Efficacy and Safety Data
Project Oncology®
Sacituzumab Govitecan for mTNBC: A Review of Real-World Efficacy and Safety Data
- Charles Turck, PharmD, BCPS, BCCCP
- Paolo Tarantino, MD
Newly Diagnosed Multiple Myeloma: The Prognostic Significance of Lymphopenia
Newly Diagnosed Multiple Myeloma: The Prognostic Significance of Lymphopenia
Project Oncology®
Newly Diagnosed Multiple Myeloma: The Prognostic Significance of Lymphopenia
Targeting HER2-Mutant NSCLC with Trastuzumab Deruxtecan: Initial Study Findings
Targeting HER2-Mutant NSCLC with Trastuzumab Deruxtecan: Initial Study Findings
Project Oncology®
Targeting HER2-Mutant NSCLC with Trastuzumab Deruxtecan: Initial Study Findings
- Jacob Sands, MD
- Julia Rotow, MD
Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC
Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC
MinuteCE®
Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC
1.50 program credits
- Peter Schmid, FRCP, MD, PhD
1.50 program credits

Programs

Treating Second-Line NSCLC: The Efficacy of ADCs Targeting Predictive Biomarkers
Treating Second-Line NSCLC: The Efficacy of ADCs Targeting Predictive Biomarkers
Project Oncology®
Treating Second-Line NSCLC: The Efficacy of ADCs Targeting Predictive Biomarkers
- Charles Turck, PharmD, BCPS, BCCCP
- Laura Alder, MD
Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors
Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors
MinuteCE®
Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors
1.50 program credits
- Erica L. Mayer, MD, MPH
1.50 program credits
Current Guideline Recommendations for Biomarker-Based Second-Line Treatment of mCRC
Current Guideline Recommendations for Biomarker-Based Second-Line Treatment of mCRC
MinuteCE®
Current Guideline Recommendations for Biomarker-Based Second-Line Treatment of mCRC
1.25 program credits
- Aparna R. Parikh, MD
1.25 program credits
Novel Neoadjuvant and Adjuvant Immunotherapy Strategies for GI Malignancies: The Evidence
Novel Neoadjuvant and Adjuvant Immunotherapy Strategies for GI Malignancies: The Evidence
MinuteCE®
Novel Neoadjuvant and Adjuvant Immunotherapy Strategies for GI Malignancies: The Evidence
1.25 program credits
- Alan Venook, MD
1.25 program credits